Xiamen Amoytop Biotech Co. Ltd

After 14-year development, the long-acting interferon drug product developed by Amoytop Biotech, Pegbing (Mipeginterferon alfa-2b), a national class-1 new drug, was approved in China in 2016. Pegbing is the first 40kD Y-shape branded PEG-modified interferon alfa-2b injection in the world. With a special structure under complete patent protection, it has broken the monopoly of foreign products in treatment of viral hepatitis, and was awarded with “2016 Top 10 China Medicinal Biotech Progress” by China Medicinal Biotechnology Association. Recently, with the idea of “clinical cure” in chronic hepatitis B treatment field gradually recognized by hepatitis specialists and clinicians, Amoytop Biotech has supported and conducted a series of research projects aiming to improve CHB clinical cure level, including CHB clinical cure projects listed in the National Major Scientific and Technological Special Projects during the “13th Five-year Plan” period, exploratory researches on the application and optimization of chronic hepatitis B clinical cure, and relevant confirmatory clinical trials. Through continuous exploration and accumulation, Amoytop Biotech is devoted to being the leader in the field of CHB clinical cure based on pegylated interferon alfa-2b.